A Series B team reached out last week. They'd gotten a demo of Weave Bio, were impressed, but the contract was "too much right now." They wanted to know if Regfo was the same thing, cheaper.
It's not the same thing. And knowing that upfront saves you from evaluating tools that don't match your actual problem.
What Weave Bio Actually Does
Weave Bio is a regulatory authoring platform. Their core product, AutoIND, helps teams generate the documents that go into an eCTD submission — module sections, summaries, narratives, formatted outputs. You bring study data; the platform helps you write and organize the submission package.
It handles version control, team collaboration, data traceability back to source files in two clicks, and eCTD formatting. Think of it as a document production environment for people who are actively building a submission.
They've raised $36M total (including a $20M Series A announced in October 2025), partnered with Parexel, and have around 30 people on the team. That's a real product for a real problem. Writing CTD modules by hand is painful. Keeping five people aligned on a living document package is worse.
But writing documents is a different problem from knowing what needs to go in them. That's where teams get tripped up when comparing the two.
What Regfo Does
Regfo is a compliance checker. You upload a study report or paste protocol text, and the system runs it against FDA/ICH requirements and tells you what's wrong — before you submit anything.
The output is specific. Not "consider reviewing safety pharmacology requirements" but: your respiratory battery is missing per ICH S7A, your hERG assay isn't documented as GLP-compliant, the exposure margin calculation expected in your nonclinical overview is absent. Each finding cites the exact guideline section.
Regfo doesn't write documents. It reads what you have and tells you whether it'll survive FDA review. The rules engine covers 373 requirements across 24 FDA/ICH guidelines. Analysis runs in under 30 seconds. Pricing starts at $399/month, with a free tier.
The Core Difference
| Regfo | Weave Bio | |
|---|---|---|
| What it does | Checks compliance gaps in studies and protocols | Authors and formats eCTD submission documents |
| When to use | During protocol writing, pre-IND review | During active submission preparation |
| Input | Protocol text or study reports | Raw study data and reports |
| Output | Compliance findings with guideline citations | Formatted eCTD documents |
| Pricing | Free tier → $399/mo → $999/mo | Enterprise custom (contact sales) |
| Self-serve? | Yes — analyze a study today | No — requires demo and negotiation |
| G2/Capterra reviews | Growing | Zero public reviews as of April 2026 |
| Best fit | Series A-C, 5-50 employees, pre-submission | Series B+ with active submission in progress |
When Weave Bio Makes Sense
You're building an actual eCTD submission right now. Your team is large enough that document collaboration and version control are real pain points. You have budget for an enterprise contract and time for a proper software evaluation. You're producing submissions at scale — either as a large biotech or a CRO with multiple clients.
The Parexel partnership tells you something about positioning: this is built for organizations that have already figured out what they're submitting and need help with the production of it.
One thing worth knowing: Weave Bio has zero public reviews on G2 or Capterra as of this writing. That's not unusual for an early-stage product, but in regulated industries, you're putting your submission timeline in a platform's hands. "We're early adopters" is a reasonable position — just go in with eyes open.
When Regfo Makes Sense
You're 6–18 months from submission and still writing protocols or reviewing study reports. You want to know whether your preclinical package will hold up to FDA scrutiny before you submit. You're a Series A or B team, you don't have $50K+ for authoring tools, and you don't have a full regulatory department to run one.
For nonclinical study packages, Regfo checks things like: Does your safety pharmacology package cover all three core battery systems per ICH S7A? Are your genotoxicity studies GLP-compliant? Do your repeat-dose tox study durations match the intended clinical exposure period per ICH M3(R2)?
You get specific findings in 30 seconds. No contract negotiation, no implementation period, no demo required.
The Budget Reality
Weave Bio doesn't publish pricing. Based on the enterprise positioning and sales model, you're looking at $50K–$150K per year — appropriate for what the product offers. That's not a criticism; it reflects the scope of what they've built.
Regfo publishes pricing on the website: free to start, $399/month Pro, $999/month Team. The difference is whether this is an expense-it tool or a board-approved procurement.
Neither is wrong. The mistake is evaluating them against each other as if they compete for the same budget.
Can You Use Both?
Yes. The overlap is small enough that it's not either/or.
Use Regfo to check your preclinical studies and protocols and fix compliance gaps before they become amendment cycles or clinical holds. Then use Weave Bio (or your regulatory team, or a consultant) to author and format the actual submission package.
Regfo answers: "Is this study ready to be included in my IND?" Weave Bio answers: "How do I format all of this into a proper eCTD?" Those are sequential questions, not competing ones.
The Honest Take
Weave Bio is building something genuinely ambitious. End-to-end AI authoring for regulatory submissions is hard, and they have the funding and team to do it properly. If the product delivers, it'll be valuable for teams doing high-volume submission work.
But if you're a Series A biotech working on your first IND, you probably don't need an authoring platform. You need to know whether your preclinical package will survive FDA review.
That's what Regfo does.
Upload a study, get specific findings in 30 seconds, each one with the exact guideline citation. Try it free — no demo call, no contract. Run it on something you already have and see what comes back.
FAQ
Is Regfo a replacement for Weave Bio?
No. They solve different problems at different stages. Weave Bio is a document authoring platform — it helps teams write and format eCTD submission packages. Regfo is a compliance checker — it reads your existing protocols and study reports and tells you whether they meet FDA/ICH requirements before you submit. If you're 6–18 months from your IND, Regfo is the relevant tool. If you're actively building the submission package right now, Weave Bio addresses a different need.
What does Weave Bio's AutoIND actually do?
AutoIND is Weave Bio's core product. It takes your study data and helps generate the document sections that make up a CTD/eCTD submission — module narratives, summaries, formatted outputs — with version control and team collaboration built in. The Parexel partnership showed it can complete IND applications 50% faster than traditional timelines. It's an authoring and production environment, not a compliance checking tool.
How much does Weave Bio cost compared to Regfo?
Weave Bio doesn't publish pricing. Based on their enterprise sales model and positioning (Parexel as a design partner, $36M raised), expect custom contracts in the $50K–$150K/year range. Regfo publishes pricing directly: free tier to start, $399/month for Pro, $999/month for Team. The difference is whether this is a board-approved procurement or something you expense and start using today.
Can I use both Regfo and Weave Bio together?
Yes, and the workflow makes sense sequentially. Use Regfo to catch compliance gaps in your preclinical studies and protocols before you start building the submission. Then use Weave Bio (or a regulatory consultant, or your internal team) to author and format the actual eCTD package. Regfo answers "is this study ready to include?" — Weave Bio answers "how do I format everything into a submission?" Those are consecutive steps, not competing ones.